Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI). J of Skin [Internet]. 2023 Nov. 13 [cited 2026 Apr. 30];7(6):s238. Available from: https://skin.dermsquared.com/skin/article/view/2355